Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Transplant Cell Ther. 2021 Apr 6;27(7):617.e1–617.e7. doi: 10.1016/j.jtct.2021.03.028

Table 1.

Respondent Characteristics

Characteristics N (%)
Total 175 (100)
Age (years)
30–40 33 (18.9)
41–60 92 (52.6)
≥61 50 (28.6)
Gender
Female 55 (31.4)
Male 119 (68.0)
Prefer not to respond 1 (0.6)
Years of post-training experience in alloHCT
≤10 61 (34.9)
11–20 38 (21.7)
>20 76 (43.4)
Practice setting
Teaching hospital affiliated with university academic center 150 (85.7)
Other* 25 (14.3)
Annual alloHCT volume by center
<49 41 (23.4)
50–199 78 (44.6)
≥200 56 (32.0)
*

Other practice settings by physician report included: teaching hospital not affiliated with university/academic center (n=12); non-teaching hospital (n=10); government hospital- National Institutes of Health clinical center; National Cancer Institute-designated cancer center; and office/clinic not affiliated with a hospital

Note: alloHCTs indicates allogeneic hematopoietic cell transplant